重组人生长激素临床应用的安全性思考  

Safety considerations for the clinical application of recombinant human growth hormone

作　　者：潘慧[1] 杜红伟[2] PAN Hui;DU Hong-Wei(Department of Pediatrics,First Bethune Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]北京协和医院内分泌科,北京100032 [2]吉林大学白求恩第一医院儿科,吉林长春130021

出　　处：《中国当代儿科杂志》2024年第5期444-449,共6页Chinese Journal of Contemporary Pediatrics

摘　　要：重组人生长激素(recombinant human growth hormone,rhGH)是改善身材矮小的有效治疗药物,目前rhGH可应用于包含生长激素缺乏症在内的多种原因导致的身材矮小,临床应用的扩展使其安全性问题备受关注。基于现有证据,当rhGH规范应用于生理性替代治疗时,其安全性较好。临床中,应用rhGH进行治疗期间可结合文献证据和临床经验重点关注短期安全性,长期安全性由于rhGH治疗时间不足尚无准确定论。该文梳理了在rhGH治疗过程中有可能出现的不良事件及其风险控制措施,旨在帮助临床医生了解rhGH治疗的整体安全性,改善临床规范化应用。Recombinant human growth hormone(rhGH)is an effective therapeutic drug for improving short stature.Currently,rhGH can be used for various causes of short stature,including growth hormone deficiency,and the expansion of its clinical application has raised concerns about its safety.Based on existing evidence,when rhGH is used in a standardized manner for physiological replacement therapy,its safety profile is favorable.In clinical practice,attention should be focused on short-term safety during rhGH treatment,with the combination of literature evidence and clinical experience.There is still no definitive conclusion on the long-term safety due to insufficient duration of rhGH treatment.This paper reviews the possible adverse events that may occur during rhGH treatment and their risk control measures,aiming to help clinical physicians understand the overall safety of rhGH treatment and improve its clinical standardization.

关 键 词：重组人生长激素 临床安全性 不良事件 风险控制 

分 类 号：R977.1[医药卫生—药品]